Additionally, new research indicates that tirzepatide potentially has some advantages over traditional metabolic regulation, such as insulin sensitivity improvement and anti-inflammatory effect [2]
It showed that a lot of the lean mass lost was in organs, like the liver, which lost fat mass (decreased fatty liver)
Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study
Mounjaro/Zepbound (tirzepatide), approved dual GLP-1/GIP agonist for type 2 diabetes and obesity Recent Highlights: In April 2026, the FDA approved orforglipron (Foundayo), making it one of the first oral GLP-1 pills that can be taken any time of day and that has no food or water restrictions
As a result, payers are seeking cost-effective alternatives that address the root causes of these conditions and promote sustainable behavior change
Lifestyle fundamentals still rule as the most important sustainable body composition change drivers
